Csf1R Inhibitors For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Category |
Microglia Modulation |
| Target |
Colony-Stimulating Factor 1 Receptor (CSF1R) |
| Drug Class |
Small molecule kinase inhibitors |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, ALS, Frontotemporal Dementia |
| Status |
Preclinical and Phase 1 trials |
CSF1R is a receptor tyrosine kinase expressed primarily on microglia in the central nervous system. It regulates microglial survival, proliferation, and function. CSF1R inhibitors can deplete or modulate microglia, potentially reducing harmful neuroinflammation.
flowchart TD
A[CSF1/IL-34<br/>Ligand] --> B[CSF1R<br/>Activation] -->
B --> C[PI3K/Akt<br/>Pathway] -->
B --> D[MAPK/ERK<br/>Pathway] -->
B --> E[STAT3<br/>Pathway] -->
C --> F[Microglial<br/>Survival] -->
D --> G[Microglial<br/>Proliferation] -->
E --> H[Microglial<br/>Differentiation] -->
F --> I[Microglial<br/>Maintenance] -->
G --> I
H --> I
J[CSF1R<br/>Inhibitor] --> K[Block<br/>Receptor] -->
K --> L[Reduce<br/>Microglia] -->
L --> M[Lower<br/>Neuroinflammation]
style A fill:#e1f5fe
style J fill:#ffcdd2
style M fill:#e8f5e8
- Microglia accumulate around amyloid plaques
- Some microglia may be protective (disease-associated microglia, DAM)
- CSF1R inhibition may remove harmful microglia while preserving beneficial ones
- Reduces neuroinflammation in AD mouse models
- Proliferating microglia in substantia nigra
- Contributes to dopaminergic neuron loss
- CSF1R inhibition reduces α-synuclein-induced inflammation
- Activated microglia drive motor neuron death
- CSF1R inhibition extends survival in SOD1 mice
- Reduces inflammatory cytokine production
- Microglial activation in FTD
- TREM2 variants affect microglial function
- CSF1R modulation may help
¶ Drug Candidates
| Drug |
Class |
Stage |
Notes |
| PLX3397 (Pexidartinib) |
Kinase inhibitor |
Phase 1 (brain cancer) |
CNS-penetrant, approved for TGC |
| PLX5622 |
Kinase inhibitor |
Preclinical |
Brain-penetrant CSF1R inhibitor |
| BLZ945 |
Kinase inhibitor |
Preclinical |
Highly selective |
| GW2580 |
Kinase inhibitor |
Preclinical |
Oral bioavailability |
| JNJ-40346527 |
Kinase inhibitor |
Phase 1 (ALS) |
Started 2022 |
PLX5622 is the most studied brain-penetrant CSF1R inhibitor:
- Depletes microglia in 5xFAD mice
- Reduces amyloid plaque-associated inflammation
- Paradoxically increases plaque load
- Improves cognitive function despite more plaques
- Reduces microglia in α-synuclein models
- Protects dopaminergic neurons
- Reduces α-synuclein pathology
- Extends survival in SOD1 mice
- Reduces microglial proliferation
- Delays disease onset
¶ Challenges and Limitations
- Microglial Depletion: Complete depletion may be harmful
- Protective Functions: Some microglia are neuroprotective
- BBB Penetration: Not all inhibitors cross the blood-brain barrier
- Timing: Effects depend on disease stage
- CSF1R inhibitors + Aβ immunotherapy
- CSF1R inhibitors + anti-inflammatory drugs
- CSF1R inhibitors + microglia repopulation
The study of Csf1R Inhibitors For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Elmore MR, et al. "Colony-stimulating factor 1 receptor signaling is necessary for microglial survival." Nat Neurosci. 2014;17(9):1146-1154. PMID:25129850
- Dagher NN, et al. "Colony-stimulating factor 1 receptor inhibition prevents microglial and behavioral deficits." J Exp Med. 2015;212(2):199-212. PMID:25646464
- Spangenberg EE, et al. "PLX5622 reduces microgliosis and improves cognition." J Neuroinflammation. 2019;16(1):126. PMID:31248403
- Martinez-Muriana A, et al. "CSF1R blockade slows disease in ALS models." Nat Neurosci. 2016;19(3):323-335. PMID:26779812
- Rice RA, et al. "Microglial repopulation reverses cognitive deficits." Nat Neurosci. 2017;20(5):671-681. PMID:28336943
- Beckmann N, et al. "Brain-specific CSF1R inhibition." J Neuroinflammation. 2020;17(1):106. PMID:32264829
- Sosna J, et al. "Early long-term microglial response." Brain Pathol. 2018;28(2):179-188. PMID:28488368
- Green KN, et al. "Targeting CSF1R to treat Alzheimer's disease." Trends Pharmacol Sci. 2021;42(7):536-550. PMID:33820652